For instance, the toxin-conjugated chimeric antibody, brentuximab vedotin (Adcetris), which binds to CD30, has been approved for the treatment of HL and anaplastic large-cell lymphoma (ALCL), two malignancies that express high surface levels of CD30 (Table 1). Here, TNFRSF8 is linked to Hodgkins lymphoma.